It hurt.” Besides pain and watery diarrhea, symptoms include: fever and sometimes nausea and vomiting. Patients usually become dehydrated and go to their doctors. C. diff is treated with oral ...

A new study on Clostridioides difficile infections finds that choosing an alternative antibiotic for high-risk patients with pneumonia can reduce infection risk. C. diff infections can be deadly, and ...

SALT LAKE CITY – Over the past two decades there has been a sharp rise in the number and severity of infections caused by the bacteria Clostridium difficile often shortened to C. diff now the most ...

(Reuters) - Drugmakers racing to develop medicines and vaccines to combat a germ that ravages the gut and kills thousands have a new challenger: the human stool. For patients hit hardest by the ...

Anne J. Gonzales-Luna, research assistant professor in the Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, is reporting the weakening of ...

Charles Darkoh, Ph.D., a researcher at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health, was recently awarded a five-year, $1.9 million R01 grant by the ...

Vowst is a prescription drug that’s used in adults to help prevent Clostridioides difficile (C. diff) infection from coming back after it has been treated. Vowst comes as an oral capsule. Vowst ...

A new study from the University of Birmingham has shown that Faecal Microbiota Transplants (FMT) are highly successful in treating patients with Clostridioides difficile (C.diff) infection. Published ...

Purpose The pharmacology, clinical efficacy, safety, dosage and administration, and place in therapy of fidaxomicin for the treatment of Clostridium difficile infection (CDI) are reviewed. Conclusion ...

Christian John Lillis, cofounder and executive director of the Peggy Lillis Foundation for C difficile Education & Advocacy, explained how FDA-approved microbiome-based therapeutics help to treat and ...

Seres Therapeutics reported results from an interim phase 2 trial for its colon infection treatment weren’t found to be statistically significant. 1. The treatment, SER-109, is intended for multiply ...